Eli Lilly and Company announced it will invest over $1 billion in contract manufacturing partnerships in India to increase the global supply of its drugs for obesity, diabetes, Alzheimer's, cancer, and autoimmune conditions. As part of this strategic investment, the company will also establish a new manufacturing and quality hub in Hyderabad to oversee its local contract manufacturing network. This initiative is intended to leverage India's skilled workforce to support Lilly's global growth. The investment is one of the largest in the Indian pharmaceutical sector in recent years and aligns with Lilly's commitment of over $55 billion since 2020 to expand its worldwide manufacturing capabilities.